Seattle genetics and astellas announce padcev improved overall survival in phase 3 trial in previously treated locally advanced urothelial cancer

Seattle genetics and astellas announce padcev® (enfortumab vedotin-ejfv) significantly improved overall survival in phase 3 trial in previously treated locally advanced or metastatic urothelial cancer.seattle genetics inc - trial stopped early due to positive results at planned interim analysis.seattle genetics inc - data intended to support global registrations and convert accelerated to regular approval in u.s.seattle genetics inc - phase 3 trial of padcev met its primary endpoint.seattle genetics inc - results will be submitted to u.s. fda as confirmatory trial following drug's accelerated approval in 2019.seattle genetics inc - for patients in padcev arm of trial, adverse events were consistent with those listed in u.s.
SGEN Ratings Summary
SGEN Quant Ranking